Episode Details
Back to Episodes
Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases
Published 1 week ago
Description
Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.